Suchergebnisse - "Rejeski, Kai"

PubPharm (5)

1

Recognizing, defining, and managing CAR-T hematologic toxicities

enthalten in: Hematology. American Society of Hematology. Education Program | 2023

von Rejeski, K. | Subklewe, M. | Locke, F.

2

Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2023

von Kampouri, E. | Little, J. | Rejeski, K. | +3

3

Immune effector cell-associated hematotoxicity : EHA/EBMT consensus grading and best practice recommendations

enthalten in: Blood | 2023

von Rejeski, K. | Subklewe, M. | Aljurf, M. | +34

CommentIn: Blood. 2023 Sep 7;142(10):859-861. - PMID 37676695

4

Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma

enthalten in: Transplantation and cellular therapy | 2023

von Rejeski, K. | Jain, M. | Smith, E.

5

AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms

enthalten in: Oncogene | 2021

von Rejeski, K. | Duque-Afonso, J. | Lübbert, M.

1
[1]